TGF-β signaling is considered to be an attractive molecular target for cancer therapy, and inhibitors of TGF-β signaling, such as receptor kinase inhibitors, neutralizing antibodies, and antisense oligonucleotides, have been used in pre-clinical trials15. The gene discussed is TGFB1; the disease is cancer.